Advertisement
IMNM vs SLDB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a Hold and SLDB is a StrongBuy.
IMNM sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for IMNM moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
IMNM broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMNM entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMNM's RSI Indicator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMNM as a result. In 68 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for IMNM just turned positive on October 22, 2026. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +11.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 235 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.047) is normal, around the industry mean (3.482). P/E Ratio (-7.395) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for SLDB turns positive, indicating new upward trend
SLDB saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 69 similar instances where the indicator turned positive. In 59 of the 69 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Indicator exited the oversold zone, 33 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +8.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SLDB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SLDB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.889) is normal, around the industry mean (3.482). P/E Ratio (-3.487) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMNM | SLDB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | 59 | |
P/E GROWTH RATING 1..100 | 27 | 20 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SLDB's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for IMNM (70) in the null industry. This means that SLDB’s stock grew somewhat faster than IMNM’s over the last 12 months.
IMNM's Profit vs Risk Rating (95) in the null industry is in the same range as SLDB (100) in the Biotechnology industry. This means that IMNM’s stock grew similarly to SLDB’s over the last 12 months.
IMNM's SMR Rating (98) in the null industry is in the same range as SLDB (98) in the Biotechnology industry. This means that IMNM’s stock grew similarly to SLDB’s over the last 12 months.
SLDB's Price Growth Rating (59) in the Biotechnology industry is in the same range as IMNM (62) in the null industry. This means that SLDB’s stock grew similarly to IMNM’s over the last 12 months.
SLDB's P/E Growth Rating (20) in the Biotechnology industry is in the same range as IMNM (27) in the null industry. This means that SLDB’s stock grew similarly to IMNM’s over the last 12 months.
| IMNM | SLDB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 86% |
| Advances ODDS (%) | 5 days ago 82% | 4 days ago 79% |
| Declines ODDS (%) | 3 days ago 86% | 6 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 75% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMNM’s FA Score shows that 1 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).
- IMNM’s FA Score: 1 green, 4 red.
- SLDB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMNM’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).
- IMNM’s TA Score: 5 bullish, 4 bearish.
- SLDB’s TA Score: 5 bullish, 3 bearish.
Price Growth
IMNM (@Biotechnology) experienced а +2.75% price change this week, while SLDB (@Biotechnology) price change was +6.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
IMNM is expected to report earnings on Mar 25, 2027.
SLDB is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMNM and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To IMNM | 1D Price Change % | ||
|---|---|---|---|---|
| IMNM | 100% | +4.50% | ||
| KYTX - IMNM | 59% Loosely correlated | +5.86% | ||
| SLDB - IMNM | 53% Loosely correlated | +6.63% | ||
| EDIT - IMNM | 52% Loosely correlated | +0.78% | ||
| LXEO - IMNM | 50% Loosely correlated | -0.52% | ||
| FDMT - IMNM | 49% Loosely correlated | +8.89% | ||
More | ||||